TOX 21: New Dimensions of Toxicity Testing by Schmidt, Charles W.
News | FocusFocus  | Tox21: New Dimensions of Toxicity Testing
A 349
TOX21
New Dimensions 
of Toxicity Testing 
O
n the ground floor of the National 
Institutes  of  Health  Chemical 
Genomics Center (NCGC) in Rockville, 
Maryland, a $10-million automated labo-
ratory spends all day and night screening 
chemicals at speeds no team of human 
researchers could ever match. In a week, 
depending on the nature of the assay, it can 
yield up to 2.2 million molecular data points 
derived from thousands of chemicals tested 
at 15 concentrations each. 
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Is this the new face of toxicology? Many 
experts say the answer could be yes. High-
throughput screening tools such as the 
NCGC’s robotic system—combined with 
a growing assortment of in vitro assays and 
computational methods—are revealing how 
chemicals interact with biologic targets. 
Scientists increasingly believe these tools 
could generate more accurate assessments 
of human toxicity risk than those predicted 
by animal tests now. What’s more, in vitro
analytical approaches are seen as the best 
hope for evaluating the enormous back- hope for evaluating the enormous back- hope for evaluating the enormous back
log of untested chemicals in commerce. 
Estimates vary, but tens of thousands of 
industrial chemicals are used in consumer 
products without any knowledge of their 
potential toxicity. Meanwhile, it takes years 
and millions of dollars to assess risks for a 
single chemical using animal testing. 
“In almost all aspects, this looks like 
a paradigm shift in the field,” says John 
Bucher, associate director of the National 
Toxicology Program (NTP). “It’s a major 
change to move from using studies in ani-
mals, with which we’re comfortable, to rely- mals, with which we’re comfortable, to rely- mals, with which we’re comfortable, to rely
ing mainly on results from biochemical or 
cell-based assays to make health policy deci-
sions. This is a totally different approach that 
provides a different kind of information.” 
The Tox21 Partnership
Enabled by new technology, the NTP, the 
NCGC, and the U.S. Environmental Pro-
tection Agency (EPA) are partnering to 
advance the state of toxicity testing. Spe-
cifically, the partners seek to identify new 
mechanisms of chemical activity in cells, 
to prioritize the backlog of untested chemi-
cals for more extensive evaluations, and to 
develop better predictive models of human 
response to toxicants. Formalized last year 
in a Memorandum of Understanding, the 
partnership, dubbed Tox21, responds to a 
challenge made by the National Research 
Council (NRC) in its 2007 report Toxicity
Testing in the 21st Century: A Vision and a 
Strategy. This report called for transform-
ing toxicology “from a system based on 
whole-animal testing to one founded pri-
marily on in vitro methods that evaluate 
changes in biologic processes using cells, 
cell lines, or cellular components, prefer-
ably of human origin.” In March 2009, 
the EPA published its own Tox21 agenda, 
The U.S. Environmental Protection Agency’s 
Strategic Plan for Evaluating the Toxicity of 
Chemicals, which asserts that “the explo-
sion of new scientific tools in computation-
al, informational, and molecular sciences 
offers great promise to . . . strengthen toxic-
ity testing and risk assessment approaches.”
The concept of adding more mechanis-
tic data to risk assessment isn’t new. Before 
Tox21, physiologically based pharmaco-
kinetic (PBPK) models, toxicogenomics, 
and related approaches were already mak- and related approaches were already mak- and related approaches were already mak
ing risk assessment more mechanistically 
based. But that research didn’t necessarily 
translate into changes in regulatory policies 
that govern human exposure, argues Lorenz 
Rhomberg, a principal with Gradient 
Corporation, a risk assessment consulting 
firm in Cambridge, Massachusetts. Despite 
the availability of mechanistic data, health 
officials at the EPA have been reluctant to 
use these data in setting exposure standards 
because in many cases they would justify 
higher allowable exposures than those 
suggested by more conservative default 
assumptions. Instead, the EPA relies more 
often on conservative default assumptions 
about how chemicals affect human beings. 
“EPA goes by precedent and does things as 
it did in the past so as to not be arbitrary,” 
Rhomberg explains. “So, there’s a lot of 
inertia in the system.” 
Robert Kavlock, director of the EPA 
National Center for Computational Toxicol-
ogy, says the main difference between Tox21 
and prior molecular research in toxicology is 
one of scale. Scientists have generally focused 
on hypothesis-driven investigations, such as 
how a chemical interacts with a specific cell 
target assumed to play a role in toxicity, he 
explains. Tox21, on the other hand, relies 
on unbiased screening methods that don’t 
assume any prior knowledge about what a 
chemical might do in the cell. Those inves-
tigations ideally will reveal entirely new 
molecular networks that coordinate toxic-
ity, he says. Kavlock emphasizes that with 
its new strategy the EPA is demonstrating 
a willingness to take mechanistic data seri-
ously. “Tox21 was produced with input from 
senior members across all the EPA offices,” 
he says. “There’s an explicit recognition that 
we’re in a scientific transition and that the 
business part of the agency needs to come 
along with it.” 
A New Focus on Pathways
Tox21’s essential premise is that scientists 
can infer human harm from chemicals on 
the basis of how they activate toxicity path-
ways in cells. “Toxicity pathway” refers to 
a chemically induced chain of events that 
leads to an adverse effect such as tumor 
formation, explains Raymond Tice, chief of 
the NTP Biomolecular Screening Branch. 
        
I
t’s a major change to move from using studies in animals, 
with which we’re comfortable, to relying mainly on results 
from biochemical or cell-based assays to make health policy 
decisions. This is a totally different approach that provides a 
different kind of information.
—John Bucher
National Toxicology Program 
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Tice emphasizes that these pathways ordi-
narily coordinate normal processes such as 
hormone signaling or gene expression. It’s 
only when they are altered by chemicals or 
other stressors that harm occurs, he says. 
“We’re talking about pathways that occur 
all the time under typical circumstances,” 
Tice explains. Estrogen-receptor signaling, 
for instance, is an ordinary feature of nor- for instance, is an ordinary feature of nor- for instance, is an ordinary feature of nor
mal cell biology, “but if it’s inappropriately 
up- or down-regulated,” Tice says, “it can 
cause developmental problems.” 
Scientists are now attempting to identify 
and map toxicity pathways and the ways 
chemicals interact with the biochemical 
processes involved in cell function, commu-
nication, and the ability to adapt to envi-
ronmental changes. Ideally, these efforts 
will identify molecular “nodes” vulnerable 
to chemical exposure. An example of such a 
node could be a protein that—upon chemi-
cal binding—blocks or amplifies estrogen-
receptor signaling, altering the pathway’s 
normal function. This is called a “pathway 
perturbation.”
After identifying a perturbation, scien-
tists have to put it into a broader context of 
toxicity in living animals. Doing so requires 
them to extrapolate a toxic blood or tis-
sue dose from a cell-based response, which 
can be accomplished with PBPK model-
ing and computational methods based on 
human cell circuitry, says Gina Solomon, a 
senior scientist with the nonprofit Natural 
Resources Defense Council. Cell-based 
assays offer some advantages in this respect. 
Unlike animal tests, which are limited by 
cost and resource constraints to just a few 
doses, in vitro assays can test chemicals at 
a broad range of doses that might provide 
better information about low-dose human 
effects, scientists say. 
The whole process requires a leap of faith 
that perturbations and associated modeling 
efforts will accurately predict human effects 
from chemical exposure, Solomon says. 
“And this is why risk assessors at EPA have 
such a hard time with this type of data,” she 
explains. “It’s not easy to extrapolate from 
[the results of] a cell-based assay to [exposure 
effects] in a real population of humans. This 
is the toughest aspect of pathway-based risk 
assessment, and it’s one of the main reasons 
why it’s going to take years for these new 
approaches to come into widespread use.”
The Path Forward
Experts anticipate T ox21 will roll out in 
two phases. In the first, perturbations could 
guide the selection of chemicals for fur-
ther testing in animals. With this approach, 
chemicals that, for instance, trigger oxida-
tive stress (which can lead to inflammation) 
or impede DNA repair (thus potentially 
increasing the risk for cancer) could be given 
high-priority status for testing, whereas those 
that don’t induce such immediately worri-
some effects could be relegated to a lesser 
concern. The EPA, through its ToxCast™ 
program, is already exploring how high-
throughput systems can be used for priori-
tization, as is the NTP, in accordance with 
its own research program for the twenty-
first century—the NTP Roadmap that was 
introduced in 2004.
Kavlock says there’s a crucial need to 
prioritize chemicals on more of a biological 
basis. “Right now we’re prioritizing chemi-
cals on the basis of other criteria, such as pro-
duction volume, the likelihood for human 
exposure, or their structural similarity to 
other chemicals with known liabilities,” he 
says. “By incorporating more biology into 
prioritization, we think we can do a better 
job selecting the right chemicals for animal 
testing. We could also be more efficient in 
terms of how we conduct these tests.”
In  Tox21’s  second  phase,  which 
some stakeholders say may roll out sev-
eral decades from now, pathway perturba-
tions could replace animal tests in setting 
chemical safety standards. Compared with 
prioritization, this is a far more challeng-
ing and elusive goal. Toxicologists have 
based human standards on the results of 
animal tests for more than 50 years. Stan-
dards for noncarcinogenic chemicals, for 
instance, are defined by the maximum dose 
that causes no harm to animals in a toxic-
ity study, divided by numerical factors to 
reflect data uncertainties. Humans can 
theoretically tolerate this “reference dose” 
every day, risk-free, for a lifetime. 
Alternatively, carcinogens are regulated 
with a “cancer slope factor” that scientists 
extrapolate mathematically from doses that 
cause tumors in rodents. Tumors often 
appear only with high doses given for up to 
two years. Still, EPA regulators cautiously 
assume dose linearity for carcinogens, 
meaning even a single molecule of toxicant 
could, in theory, interact with DNA and 
cause cancer—in other words, until they 
can be convinced otherwise, EPA regula-
tors assume there is no dose threshold for 
carcinogens below which cancer risk is neg-
ligible. The cancer slope factor, therefore, 
aims to limit the number of expected can-
cers in the exposed population to no more 
than 1 in 1 million people. 
I
t’s not easy to extrapolate from a cell-based assay 
to a real population of humans. This is the toughest 
piece, and it’s one of the main reasons why it’s 
going to take years for these new approaches to come 
into widespread use.
—Gina Solomon
Natural Resources Defense Council
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The fact that animal tests rely on doses 
far higher than those found in the environ-
ment raises difficult questions about their 
relevance to humans. “I’ve spent nearly 
forty years as a toxicologist trying to relate 
high-dose  animal  studies  to  low-dose 
human risk,” says Melvin E. Andersen, 
director of the Program in Chemical Safety 
Sciences at the nonprofit Hamner Institutes 
for Health Sciences. “I now believe that’s 
impossible to do.”
But experts are divided over the degree 
to which in vitro tests can completely 
replace animals in risk assessment. Ander- replace animals in risk assessment. Ander- replace animals in risk assessment. Ander
sen’s view—backed by the NRC report, he 
says—is that testing for perturbations of 
toxicity pathways, leading to the elimina-
tion of animal tests, should be a funda-
mental goal. “EPA and the NTP want to 
use in vitro results to predict high-dose 
outcomes in animals,” he says. “But that’s 
backwards—we need to identify cellular 
targets and then predict what’s going to 
happen to people at environmentally rel-
evant concentrations. In vitro methods will 
provide better information for such health 
risk assessment than animal studies. We 
have to stay current with where modern 
biology is going. If we don’t, much of what 
we do in toxicity testing will be regarded as 
irrelevant.” 
Daniel  Krewski,  director  of  the 
R. Samuel McLaughlin Centre for Popula-
tion Health Risk Assessment at the Univer- tion Health Risk Assessment at the Univer- tion Health Risk Assessment at the Univer
sity of Ottawa and chair of the NRC panel 
that produced the 2007 report, shares that 
view. “Let me say this in plain English,” 
he says. “The thrust of our vision, and also 
its beauty, is that we will no longer have to 
regulate on the basis of avoiding what we 
see in animals but on avoiding perturba-
tions that we see in cell-based tests.” 
The EPA approach is more conserva-
tive, however, and focuses on prioritizing 
chemicals for further screening in animals 
rather than eliminating animals altogether. 
Kavlock emphasizes that if new tech-
nologies help scientists select appropriate 
chemicals for animal testing, they will go a 
long way toward making the process more 
effective and more efficient. “Predicting 
the future isn’t easy,” Kavlock says. “So, I 
wouldn’t rule in or rule out that someday 
we might be able to do [toxicity testing] 
without animals. But for the foreseeable 
future, the state of the science just doesn’t 
allow for that.” 
Overcoming the Status Quo
What animal tests have going for them—
apart from a long history in toxicology and 
a regulatory structure built around their 
results—is that they integrate responses 
across physiologic systems. Toxicity is 
sometimes caused not by a “parent” com-
pound—the actual chemical to which an 
animal or human is exposed—but by a 
metabolite of that compound. Moreover, 
some chemicals, including some develop-
mental and neurotoxic compounds, aren’t 
toxic at the point of exposure but rather 
at locations elsewhere in the body. John 
Doull, professor emeritus at the Univer-
sity of Kansas Medical Center, gives the 
example of chemicals that target certain 
regions in the brain whose toxic effects are 
reflected elsewhere, perhaps in terms of gait 
or vision.
Cell-based assays might not pick up 
these metabolic or downstream effects, 
however. A study done in isolated liver 
hepatocytes, for example, might miss toxic-
ity that occurs only in whole liver, where 
adjoining cells can metabolize parent chem-
icals to toxic forms, for instance by what’s 
known as cytochrome P450-mediated 
activation. 
Christopher Austin, director of the 
NCGC, concedes metabolic activation 
poses a tough challenge for in vitro research, 
but not one that can’t be overcome. “This is 
a very hard problem to deal with,” Austin 
says. “And we’re approaching it through a 
major technology development initiative 
involving co-cultures of hepatocytes and 
P450-responsive cells. That way, we only 
see the P450-mediated response if the par- see the P450-mediated response if the par- see the P450-mediated response if the par
ent compound is metabolized.” 
Another shortcoming with in vitro test-  test-  test
ing is compound integrity. Most laborato-
ries store chemicals in dimethyl sulfoxide 
(DMSO), a popular solvent that can dis-
solve both polar (i.e., miscible with water) 
and nonpolar compounds. But DMSO can 
also absorb water from the atmosphere and 
R
ight now we’re prioritizing chemicals on the 
basis of other criteria, such as production 
volume, the likelihood for human exposure, 
or their structural similarity to other chemicals with 
known liabilities. By incorporating more biology 
into prioritization, we think we can do a better job 
selecting the right chemicals for animal testing.
—Robert Kavlock
National Center for Computational Toxicology
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explains Adam Yasgar, a research associate 
at NCGC. “The absorbed water can lead 
compounds to precipitate, which interferes 
with the analysis,” he says. “You might not 
know exactly what you’re testing.” 
Yasgar adds that NCGC gets around 
this problem by testing compounds at 
many different concentrations. The redun-
dancy of that process leads to more reli-
able data, he says. But laboratories that 
rely on single-dose analyses could run into 
problems, he adds. Kavlock points out that 
Tox21 plans on chemical characteriza-
tion of solutions being tested in order to 
confirm the identity of the chemical, its 
purity, and its stability in DMSO—an 
expensive but necessary step, he says, to 
build confidence in the resulting data.
The Current Agenda
Tox21 investigators are now conducting 
proof-of-principle experiments to show 
that pathway perturbations can pre-
dict toxicities already documented in 
completed animal studies. Their research 
focuses in part on roughly 10,000 com-
pounds, including industrial chemicals, 
pesticide  active  and  inert  ingredi-
ents, drinking water contaminants, and 
approved drugs, among others. According 
to a review in the May 2009 issue of EHP
by Richard Judson and colleagues, there 
is at least limited hazard information for 
about two-thirds of these compounds and 
detailed toxicology information for about 
one-quarter of them. The compounds are 
being screened both at the EPA—through 
ToxCast—and at NCGC, which is about 
to purchase yet another robotic laboratory 
devoted exclusively to Tox21 research. 
Kavlock says the screens test for a range 
of end points, such as interactions with 
nuclear receptors, up-regulation of the 
p53 tumor suppressor gene, and effects on 
DNA repair mechanisms. 
Meanwhile, scientists are working to 
identify and map as many toxicity pathways 
as possible. Just how many pathways might 
participate in toxicity is a matter of some 
disagreement, however. Arguing that biol-
ogy has definable boundaries that are set by 
the genome, Andersen claims the number 
is finite. “How many pathways could there 
be?” he asks. “I don’t know. I’ve suggested, 
somewhat tongue-in-cheek, that there are 
exactly 132 of them! The main point is that 
biology has to be robust, which compels 
us to believe these pathways are conserved 
across species [and through evolution]. My 
personal view is that all toxicity pathways 
revolve around stress responses and the 
control of gene expression.” Seen this way, 
Andersen adds, multiple classes of chemi-
cals could share the same toxicity path-
ways in spite of differences in their physical 
structure. 
But Katrina Waters, a senior research 
scientist at Pacific Northwest National 
Laboratory in Richland, Washington, 
asserts the number of toxicity pathways 
might be virtually unlimited. “When you 
consider the diversity of chemicals fac-
ing testing and their potential effects, I 
don’t think it’s possible to say that some 
finite number of pathways will predict 
all adverse events,” she says. “I think it’s 
probable that each chemical class will 
have its own set of toxicity pathways for 
whatever adverse events are characterized 
for that class.” 
The debate is far from semantic—the 
number of toxicity pathways reflects the 
amount of work ultimately needed to meet 
the goals of Tox21. For example, Waters 
explains, if there were only 25 pathways 
involved in apoptosis, or programmed 
cell death, scientists could model those 
pathways mathematically and assume they 
capture adverse events for every chemical 
class. “You wouldn’t have to create a new 
mathematical model for each class; you 
could simply reuse the same models [and 
apply them to different chemicals],” she 
says. “But if you have a limitless number 
of pathways and conditional interactions 
between pathways, then you have to repeat 
the modeling process for every new chemi-
cal class [under investigation].” 
Going forward, Tox21 offers the oppor- Going forward, Tox21 offers the oppor- Going forward, Tox21 offers the oppor
tunity to confer the advantages of high-
throughput research on toxicology and risk 
assessment. But its promise is tempered by 
the vast research challenges that lie ahead. 
Scientists are aiming for nothing less than a 
complete map of the cell circuits that dictate 
toxicity, assembled from untold millions of 
data points, converted somehow into some-
thing useful. Regulatory officials will have 
to devise ways to replace decisions made on 
traditional end points with ones made on 
cell-based findings, Andersen says. 
Officials will also have to craft new 
strategies to explain those findings to the 
public. “Your average person on the street 
understands that when something causes 
birth defects in a rat, that’s something 
for humans to be concerned about,” says 
Solomon. “But when you base policies on 
perturbations of thyroid hormone homeo-
stasis, well, it’s going to be harder for the 
public to know what to think about that.” 
Charles W. Schmidt, MS, of Portland, Maine, has written for 
Discover Magazine, Science, and Nature Medicine. In 2002 he 
won the National Association of Science Writers’ Science-in-
Society Journalism Award.
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I
’ve spent nearly forty years as a toxi-
cologist trying to relate high-dose animal 
studies to low-dose human risk. I now 
believe that’s impossible to do.
—Melvin E. Anderson
The Hamner Institutes  for  Health Sciences
P
u
n
c
h
s
t
o
c
k
/
D
e
x
 
I
m
a
g
e